NIZATIDINE (nizatidine) by Viatris (2) is clinical pharmacology nizatidine is a competitive, reversible inhibitor of histamine at the histamine h 2 -receptors, particularly those in the gastric parietal cells. First approved in 2002.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H 2 -receptors, particularly those in the gastric parietal cells. Antisecretory Activity Effects on Acid Secretion Nizatidine significantly inhibited nocturnal gastric acid secretion for up to 12…
Worked on NIZATIDINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions